摘要
肿瘤相关巨噬细胞(TAMs)是肿瘤微环境中主要的免疫细胞,主要分为促炎抗肿瘤的M1和抗炎促肿瘤的M2型巨噬细胞。M2型巨噬细胞在肿瘤的发生、发展和转移中发挥着关键作用,通常与不良预后密切相关,成为肿瘤免疫治疗的重要靶点。纳米药物能够实现TAMs的特异性靶向,提高药物的安全性,因此,利用纳米药物调控TAMs具有广阔的应用前景。通过纳米颗粒耗竭TAMs、抑制其募集或将M2型巨噬细胞重编程为M1型巨噬细胞,或利用TAMs递送纳米药物显示出巨大的临床应用潜力。对基于TAMs调控的纳米药物在肿瘤免疫治疗中的作用进行详细阐述,并讨论其中存在的问题及建议。
Tumor-associated macrophages(TAMs)are the main immune cells in the tumor microenvironment,mainly divided into M1 type macrophages which are pro-inflammatory and anti-tumor and M2 type macrophages that are anti-inflammatory and can promote the growth of tumor.M2 macrophages play a crucial role in the occurrence,development and metastasis of tumor,are often closely related to poor prognosis,and have become an important target of tumor immunotherapy.Nanomedicine can achieve specific targeting of TAMs and improve drug safety.Therefore,the use of nanomedicine to regulate TAMs has broad application prospects.Using nanoparticles to deplete TAMs,inhibit their recruitment or reprogram M2 macrophages into M1 macrophages,or using TAMs to deliver nanomedicine has shown great potential for clinical application.In this paper,the role of TAMs-based nanomedicine in tumor immunotherapy was elaborated,and the existing problems and suggestions were discussed.
作者
高文月
马桂蕾
Gao Wenyue;Ma Guilei(Institute of Biomedical Engineering,Chinese Academy of Medical Science&Peking Union Medical College,Tianjin 300192,China)
出处
《国际生物医学工程杂志》
CAS
2023年第5期384-389,共6页
International Journal of Biomedical Engineering
基金
国家自然科学基金项目(82172089)。
作者简介
通信作者:马桂蕾,Email:magl@bme.pumc.edu.cn。
